Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma

摘要: RATIONALE Lung cancer is the leading cause of cancer-related death in world. Tyrosine kinase inhibitors (TKIs), which target mutated epidermal growth factor receptor (EGFR), have been first-line treatment late-stage lung adenocarcinoma harboring EGFR mutation. mutations are mostly identified adenocarcinoma. However, it rarely seen neuroendocrine carcinoma, and strategies remain under reported. PATIENT CONCERNS Here, we describe a 54-year-old Chinese man diagnosed with (cT4N3M1b, stage IV) differentiation L858R mutation on exon 21. He developed progressive disease liver 4 months later, biopsy metastases showed carcinoma maintained same DIAGNOSES were by biopsy. INTERVENTIONS After combined nab-paclitaxel erlotinib, patient achieved partial remission. OUTCOMES The patient's overall survival was 27 months. LESSONS This case highlights that not responsive to single-agent EGFR-TKI. application can improve its efficacy prolong survival.